Besides the extremely high cost of this model, its major limitation is an immune mismatch between the tumor and immune cells since each come from a different donor, meaning that even though CD4+ and CD8+ T cells are present in the engrafted host, they cannot be effectively recognize or kill the MHC mismatched tumor cells. The gene discussed is HLA-C; the disease is neoplasm.